Eli Lilly and Company (LLY) NYSE
961.85
-1.48(-0.15%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Eli Lilly and Company
Address
Lilly Corporate Center
Indianapolis, IN 46285
United States of America (the)
Phone
317 276 2000
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
47000
First IPO Date
June 01, 1972
Key Executives
| Name | Title | Pay | Year Born |
| David A. Ricks | Chairman & CEO | 8.92M | 1968 |
| Diogo Rau | Executive VP and Chief Information & Digital Officer | 1.06M | 1975 |
| Gordon Brooks | Group Vice President, Controller & Corporate Strategy | 1.31M | N/A |
| Patrik Jonsson | Executive VP & President of Lilly International | 1.67M | 1967 |
| Jacob S. Van Naarden | Executive VP, President of Lilly Oncology & Head of Corporate Business Development | 3M | 1985 |
| Lucas E. Montarce | Executive Vice President & Chief Financial Officer | 3.24M | 1978 |
| Anat Hakim | Executive Vice President, General Counsel & Secretary | 3.34M | 1969 |
| Daniel Skovronsky | Chief Scientific & Product Officer and President of Lilly Research Laboratories | 4.9M | 1974 |
| Donald A. Zakrowski | Senior Vice President of Finance & Chief Accounting Officer | 0 | N/A |
| Eric Dozier | Executive Vice President & Chief People Officer | 0 | 1967 |
| Michael Czapar | Director of Investor Relations | 0 | N/A |
| Frank Cunningham | Senior Vice President of Global Value & Access | 0 | N/A |
| Ruth Gimeno | Group Vice President, Diabetes, Obesity & Cardiometabolic Research and Early Clinical Development | 0 | N/A |
| Kim Macko | Senior Director of R&D Strategy and Transformation | 0 | N/A |
| Ilya Yuffa | Executive VP and President of Lilly USA & Global Customer Capabilities | 0 | 1975 |
| Kevin Hern | Vice President of Investor Relations | 0 | N/A |
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
